Vancouver, British Columbia – TheNewswire - 7 April, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio”), is a clinical stage biopharmaceutical company targeting depressive illnesses currently dosing in multiple Phase 2B clinical trials. The Company today has issued 3,428,571 common share purchase warrants (the “Warrants”), to Haywood Securities in connection with the completion... Read More